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Glutaredoxin proteins (GLXRs) are essential components of the glutathione
system that reductively detoxify substances such as arsenic and peroxides and
are important in the synthesis of DNA via ribonucleotide reductases. NMR
solution structures of glutaredoxin domains from two Gram-negative opportu-
nistic pathogens, Brucella melitensis and Bartonella henselae, are presented.
These domains lack the N-terminal helix that is frequently present in eukaryotic
GLXRs. The conserved active-site cysteines adopt canonical proline/tyrosine-
stabilized geometries. A difference in the angle of  -helix 2 relative to the
 -sheet surface and the presence of an extended loop in the human sequence
suggests potential regulatory regions and/or protein–protein interaction motifs.
This observation is consistent with mutations in this region that suppress defects
in GLXR–ribonucleotide reductase interactions. These differences between the
human and bacterial forms are adjacent to the dithiol active site and may permit
species-selective drug design.
1. Introduction
Glutaredoxins (GLXRs) are redox enzymes that are important for
the reduction of ribonucleotide reductase enzymes that synthesize
deoxynucleotides from ribonucleotides (Uhlin & Eklund, 1994).
Thus, they are required for efﬁcient and sustainable synthesis of
DNA. Additionally, GLXRs are important for detoxifying oxidizing
agents such as reactive oxygen species (ROS), transition metals and
metalloids, e.g. arsenic compounds (Fig. 1). Like other ROS defenses,
i.e. glutathione peroxidases, this enzyme is connected to the gluta-
thione pool: GLXRs catalyse the reaction of glutathione with
peroxides and metals as shown in (1). Homeostatic levels of reduced
glutathione are restored by the action of glutathione reductase
(GSR) in (2) via reducing equivalents from the pentose phosphate
shunt. Thus, the GLXR, glutathione peroxidase and glutaredoxin
reductase enzymes are attractive targets for drug-mediated ROS
ampliﬁcation.
2GSH þ ROOH  !
GLXR and GPx
GSSG þ ROH þ H2O ð1Þ
GSSG þ NADPH þ H
þ  !
GSR
2GSH þ NADP
þ: ð2Þ
GLXRs have well conserved sequences within bacteria, but their
sequences diverge between bacteria and humans. This distinctive
difference in sequence should permit selective inhibition of bacterial
GLXRs without perturbation of the host enzyme. This might kill
bacteria by inhibition of DNA synthesis and/or through increases in
ROS toxicity.
Structures have been published for several forms of human (Sun et
al., 1998; Yang et al., 1998), plant (Rouhier et al., 2007; Li et al., 2010),
budding yeast (Gibson et al., 2008; Discola et al., 2009) and Escher-
ichia coli GLXRs (Iwema et al., 2009; Fladvad et al., 2005; Xia et al.,
1992, 2001; Bushweller et al., 1994; Sodano et al., 1991). However, it
was unclear whether other bacterial GLXRs would adopt similar
conformations. The aim of this study was to expand the existing
knowledge base of GLXR structures and to ﬁnd structural trends that
might be exploited to design selective inhibitors of bacterial GLXR
that leave host enzymes unperturbed. In particular, the GLXRs fromthe pathogens Brucella melitensis and Bartonella henselae were
investigated as these organisms have signiﬁcant relevance to medical
and military biodefense. Here, we present the structures of GLXRs
from Br. melitensis and Ba. henselae and compare these structures
with the available structures from E. coli and human.
2. Methods
2.1. Protein expression and purification
GLXRs from Br. melitensis and Ba. henselae (NCBI YP_415222
and YP_033241.1; UniProt Q2YLN2 and Q6G5J5; Pfam ID PF00462;
EC 1.20.4.1) were cloned into a pAVA vector (Choi et al., 2011) and
expressed from RIL cells grown in 2 l of M9 medium supplemented
with 4 g l
 11 3 C glucose and 1 g l
 11 5 N ammonium chloride. Protein
expression was induced at an OD600 of 0.6 with 0.5 mM IPTG and
temperature reduction to 293 K for 12 h. Cell pellets were suspended
in 50 ml buffer A (20 mM HEPES pH 7, 0.3 M NaCl, 5% glycerol,
2m M DTT) supplemented with 2 mg lysozyme, freeze-fractured twice
at 193 K and then lysed using a French press. The crude lysate was
cleared by centrifugation at 15 000g and the soluble protein super-
natant was ﬁltered through a 0.22 mm GD/X membrane syringe ﬁlter
(Whatman). Nickel IMAC on 5 ml HisTrap FF columns (GE Health-
care) was used to capture the proteins from this supernatant. Non-
speciﬁc binding proteins were washed off the column with 10% buffer
B (20 mM HEPES pH 7, 0.3 M NaCl, 5% glycerol, 2 mM DTT,
300 mM imidazole). The proteins were eluted with a 50 ml gradient
from 10% to 100% buffer B and fractions containing puriﬁed protein
were pooled, cleaved with 3C protease and rerun over the HisTrap
column. The N-terminal tag introduced during cloning consisted of
an MAHHHHHHMGTLEAQTQGPGS sequence appended to the
native methionine; only the GPGS portion remained after protease
cleavage. The HisTrap ﬂowthroughs were collected, dialyzed against
NMR buffer (20 mM phosphate, 120 mM NaCl pH 6) and puriﬁed
by size-exclusion chromatography on a Superdex 75 column (GE
Healthcare) equilibrated with NMR buffer. Fractions were pooled
and concentrated via stirred cell (Amicon) to 0.5 mM for Ba. henselae
GLXR and to 1.5 mM for Br. melitensis GLXR and placed in NMR
microcells (Shigemi).
2.2. NMR data collection
For both proteins, the standard suite of NMR experiments were
acquired (Sattler et al., 1999):
15N HSQC,
13C HSQC, 3D HNCO, 3D
HNCA, 3D HN(CO)CA, 3D CBCA(CO)NH, 3D HNCACB, 3D
HCCH-TOCSY, 3D
15N-TOCSY-HSQC (70 ms mixing), 3D
15N and
13C NOESY-HSQC (80 and 120 ms mixing times) and 2D
1H/
1H
D2O-NOESY (100 ms mixing time). Two instruments were used for
data collection: Bruker Avance 500 and 600 spectrometers equipped
with cryoprobes. All data sets were collected in conventional, i.e.
nonreduced dimensionality, formats with States–TPPI quadrature
(States et al., 1982) in the indirect
13C and
1H dimensions and Rance–
Kay sensitivity enhancement (Kay et al., 1992; Cavanagh et al., 1991)
for
15N dimensions. Proton carriers were set on water and the
15N
carrier at 117 p.p.m. For  -carbon relevant spectra the
13C carrier was
set to 52 p.p.m., while for CACB spectra it was set to 45 p.p.m. and for
carbonyl spectra it was set to 176 p.p.m.. Spectra were referenced
directly to DSS in proton dimensions and indirectly in
13C and
15N
dimensions. NMR data sets were converted and processed with
NMRpipe (Delaglio et al., 1995).
2.3. Assignments and structure calculations
Backbone assignments for both proteins were determined from
pairs of triple-resonance spectra in the usual manner (Sattler et al.,
1999; Lunde et al., 2010; Leeper et al., 2010). Backbone resonance
correlations were compared and tabulated using CCPNMR (Vranken
et al., 2005) using the manual assignment mode. Side chains were
assigned from HCCH-TOCSY,
15N-TOCSY-HSQC and, in the case of
aromatic residues, a 2D
1H/
1HD 2O-NOESY. Distance constraints for
structure calculations were obtained from 2D
1H/
1HD 2O-NOESY
and 3D
15N and
13C NOESY-HSQC spectra as unassigned peak lists.
Peak intensities were exported directly from these spectra for use in
CYANA structure calculations (Gu ¨ntert, 2004), as were chemical
shifts for TALOS-generated dihedral angle restraints (Shen et al.,
2009). Hydrogen-bond constraints were determined for slowly D2O-
exchangeable backbone amideswith acceptor-atom identitiesgleaned
from preliminary structure calculations. Initially, the disulﬁde bond in
the active site was left as a pair of thiols, but was ultimately restrained
to be a disulﬁde based upon initial structure geometry and proximity.
We decided to use the structure calculations to guide this decision
since these residues are helical and the C
  shifts reside in the
ambiguous border region between 30 and 33 p.p.m.: normal C
  shifts
for reduced helical thiols range from 23.8 to 28.8 p.p.m., but oxidized
helical disulﬁde C
  atoms range from 32.8 to 47.4 p.p.m. (Sharma &
Rajarathnam, 2000). Note that no particular effort was made to
maintain this pair of cysteines in the reduced state, so they are likely
to have been oxidized spontaneously. We have not yet explored
thorough pKa calculations to determine whether these cysteines exist
as a mixed thiol/thiolate state (Sun et al., 1998; Yang et al., 1998), but
we may do so in future studies.
Seven rounds of automated NOE assignment and structure
calculation using CYANA’s CANDID tool (Herrmann et al., 2002)
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Figure 1
Diagram of the role that glutaredoxin and related enzymes play in DNA synthesis and ROS, metal and metalloid detoxiﬁcation. Abbreviated pathways utilized by
glutaredoxin and thioredoxin in DNA synthesis are highlighted in green; abbreviated ROS defense pathways are highlighted in blue.were used to calculate the structures, followed by one round
of manual calculation of 100 structures. The ﬁnal ensembles were
selected as the 20 structures with the lowest CYANA target functions.
These structures showed convergence via low r.m.s.d.s (Table 1) and
excellent covalent geometry and clash scores (Table 2) as determined
by MolProbity (Chen et al., 2010). Structure ensembles were analysed
and rendered with PyMOL (DeLano & Lam, 2005).
3. Results and discussion
3.1. Sequence conservation between domains
A BLAST search of Br. melitensis and Ba. henselae GLXR-domain
sequences against the nonredundant protein database (Altschul et al.,
1990) revealed that the E. coli GLXR3 domain was the closest known
homolog (59% identity, E value = 3   10
 20 versus 2khp). Upon
inspection of closest homologs from available human sequences, the
GLXR1 sequence was revealed to be most similar to the bacterial
GLXR3 (38% identity, E value = 1   10
 10 versus 2khp). We assume
that this represents a discrepancy in the annotation rather than a
functional difference, as human GLXR3 is signiﬁcantly less related
(25% identity, E value = 2   10
 3 versus 2khp). A ClustalW align-
ment of the sequences using the BLOSUM matrix (Henikoff et al.,
1999; Larkin et al., 2007) is shown in Fig. 2. From this comparison it is
clear that for these sequences the region surrounding the redox active
site is highly conserved (yellow box). There are very few overall
differences between the new bacterial GLXR3s and the E. coli
GLXR. However, when compared with the human GLXR1 sequence
deviations are present in an N-terminal extension ( 0), an inserted
region in loop 1 between helix 1 and  -strand 2, and variations in the
sequence of the loop between strand 2 and helix 2 and the N-terminal
end of helix 2 are observed. As shown below, this last region is
juxtaposed with the active site. As a result, we will refer to these latter
two points of variation as the human-speciﬁc loop (HSL) and the
sequence-speciﬁc helix (SSH), respectively.
3.2. Structures of glutaredoxin from Br. melitensis and Ba. henselae
NMR spectroscopy of the Br. melitensis and Ba. henselae GLXR
domains revealed reasonably well resolved spectra that were amen-
able for structural study by NMR (Fig. 3). The Br. melitensis GLXR
had a signiﬁcantly larger number of unambiguously assignable NOEs
than the Ba. henselae GLXR (Table 1). This is partially attributed
to signiﬁcantly stronger sample concentrations for the former (1.5
versus 0.5 mM), which are a result of a slight aggregation of the latter
at higher concentrations as well as lower expression yields. Thus, the
signiﬁcantly larger numbers of medium and long-range constraints,
which are also typically low signal-to-noise NOEs, for the Br. meli-
tensis protein are a consequence of its higher concentration and
structural communications
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Table 1
NMR restraints.
Ba. henselae (2klx) Br. melitensis (2khp)
Distance restraints 1107 1747
Short range, |i   j|   1 621 886
Medium range, 1 < |i   j| < 5 207 374
Long range, |i   j|   5 279 487
Dihedral 202 194
Hydrogen bonds 40 22
CYANA target function (A ˚ 2) 1.45 1.11
Dihedral r.m.s.d. ( ) 0.76 0.94
Distance r.m.s.d. (A ˚ ) 0.012 0.006
Maximum NOE violation (A ˚ ) 0.24 0.34
Table 2
Ensemble statistics.
Ensemble of 20 structures from 100 calculated structures.
Ba. henselae (2klx) Br. melitensis (2khp)
Backbone r.m.s.d. (mean) (A ˚ ) 0.52† 0.35‡
Heavy-atom r.m.s.d. (mean) (A ˚ ) 1.14† 0.82‡
Most favored (%) 83.8 90.8
Additionally allowed (%) 16.1 9.2
Generously allowed (%) 0.1 0.0
Disallowed (%) 0.0 0.0
MolProbity score (percentile) 3.57 (97th) 2.2 (99th)
† R.m.s.d. calculated over residues 3–84, excluding 1–2 and 85–89. ‡ R.m.s.d.
calculated over residues 6–92, excluding 1–5.
Figure 2
Multiple sequence alignment of the Br. melitensis, Ba. henselae and E. coli glutaredoxin 3 domains and the Homo sapiens glutaredoxin 1 domain. The black-boxed region
indicates the conserved active-site residues shared with all dithiol GLXRs, while the red-boxed region highlights the human-speciﬁc loop 2 region (HSL2) and adjacent
sequence-speciﬁc helix (SSH) region. The blue-boxed region is the additional N-terminal helix found in the human protein.improved spectral quality. Furthermore, Ba. henselae GLXR has  11
overlapped residues in the
15N HSQC, whereas Br. melitensis GLXR
only has between two and six overlapped amides depending upon the
ﬁeld at which the spectra are collected (Fig. 3), thus further reducing
the number of unambiguously assignable resonances.
Structure calculations for both the Br. melitensis and Ba. henselae
GLXR domains converged well (Table 1, Figs. 4a and 4b). Topo-
logically, these domains adhere to the expected thioredoxin fold:
         with a 2134 mixed parallel and antiparallel  -sheet with
helices on both sides of the sheet. The active-site CPYC residues are
in the expected location at the N-terminal end of helix  1. The N-
and C-terminal tails of these full-length domains are somewhat short
relative to many other proteins studied by NMR, resulting in a well
deﬁned backbone conformation over the entire domain (0.52 and
0.35 A ˚ r.m.s.d. over all backbone atoms including the N- and
C-termini). The Ramachandran statistics and MolProbity scores are
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Figure 3
15N HSQC spectra of the Ba. henselae (a) and Br. melitensis (b) GLXR domains with complete backbone and side-chain amide assignments labeled.good (Table 2) and suggest a well reﬁned structure in spite of the
heavy reliance upon the CANDID automated NOE assignment.
3.3. Comparison with other glutaredoxins: E. coli and human
The lowest energy structures for the Br. melitensis and Ba. henselae
GLXR domains were compared with structures obtained for human
GLXR1 (Fig. 4e) and E. coli GLXR3 (Fig. 4f). The most obvious
difference is the presence of an extra N-terminal helix associated with
the human domain (blue oval, Fig. 4e). On further inspection, slight
deviations in the angle of the SSH region also become apparent. In
the Ba. henselae GLXR the SSH helical angle relative to the vector
perpendicular to the  -sheet is about 45  (Fig. 4c). This angle is
similar to that of the human GLXR, which is sterically packed up
structural communications
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Figure 4
(a, b) Stereopairs of ensemble superposition for the NMR solution structures of the Br. melitensis (a) and Ba. henselae (b) glutaredoxins. The conserved pair of active-site
cysteine side chains are drawn in gray and yellow. (c) The lowest energy conformer from (a) rotated to show the angle of SSH relative to the  -sheet surface. (d) The lowest
energy conformer from (b) with a more parallel SSH angle. (e) The human glutaredoxin 1 structure with the extra N-terminal helix (blue) and the HSL/SSH region (red
trapezoid) indicated. (f)T h eE. coli glutaredoxin 3 structure. (g) Close-up view of the convergent superposition of the CPYC active-site region (left) juxtaposed with the
divergent and non-overlapping structures for the HSL/SSH regions. Only the region near the active site and the HSL/SSH regions are colored according to the above ﬁgures,
while the remainder of the proteins are drawn in white.against theC-terminal helical extension. In contrast, the Br.melitensis
species-speciﬁc helix is more reminiscent of the E. coli structure, with
an angle of about 20 . Thus, the SSH seems to vary among species at
the levels of both primary sequence and three-dimensional structure.
4. Discussion and conclusion
We have determined the NMR structures of the GLXR domains from
the pathogenic organisms Br. melitensis and Ba. henselae. These
structures are typical examples of the thioredoxin fold present in
many dithiol reductase enzymes. Furthermore, subtle differences in
the ribonucleotide reductase binding platform on the SSH and the
extension of the HSL suggest possible routes for rational species-
selective drug design. For example, mutation of the SSH in E. coli
GLXR3 allows it to thrive even in the inviable background con-
taining gene knockouts for thioredoxin 1, thioredoxin 2 and GLXR1
(Ortenberg et al., 2004). This mutation of Met43 to valine, isoleucine
or leucine in the SSH seems to exert the restoration of its viability via
enhanced interactions with ribonucleotide reductase, consistent with
studies on GLXR bound to model peptides that point to a direct
interaction with the SSH (Berardi & Bushweller, 1999). E. coli
GLXR residue Met43 is on the opposite side of the helix from the
surface expected to directly interact with ribonucleotide reductase,
which suggests that replacement by more hydrophobic residues may
adjust the position of this helix relative to the adjacent  -sheet. This
result emphasizes that the manner in which the SSH lays across this
GLXR  -sheet surface may be pertinent to interactions with ribo-
nucleotide reductase, a detail that is also relevant to GLXR isoform
and species substrate-speciﬁcity (Figs. 4c and 4d). Additionally, the
expression levels ofribonucleotide reductase, thioredoxin and GLXR
are tightly regulated so as to maintain relative stoichiometries
(Miranda-Vizuete et al., 1996). Thus, structural biology, biochemistry
and epigenetics all point to the position of the sequence-speciﬁc helix
(SSH) being important for recruitment of ribonucleotide reductase.
Whether this is through direct interactions between ribonucleotide
reductase and the SSH or whether the SSH acts as a displaceable
cover for interactions mediated by the nearby  -sheet will require
additional experiments to determine fully.
Either GLXR or thioredoxin is required for cellular viability
(Russel & Holmgren, 1988). Unlike thioredoxin, GLXR requires no
accessory enzymatic component to regenerate itself directly. Instead,
it relies directly upon the state of the glutathione pool (typically at
 99% GSH versus  1% GSSG; Higashi et al., 1985) and hence the
availability of reducing equivalents in the form of NADPH. There-
fore, as a simpler molecular system, it may be more difﬁcult to
develop resistance pathways beyond the inherent alternative pathway
provided by thioredoxin. Indeed, small-molecule inhibitors of
glutathione synthesis such as buthione sulfoximine (BSO) can reverse
resistance to cellular toxins and stress (Grifﬁth & Meister, 1979). For
example, both tumor cells and Gram-negative facultative anaerobic
bacteria are highly dependent on the glutathione pool for viability
(Smirnova et al., 2005). It has been demonstrated that tumor cells that
are resistant to radiation and chemotherapeutics can be sensitized via
co-treatment with GSH synthesis inhibitors such as BSO. In a similar
fashion, depletion of the glutathione pool using BSO-like compounds
should amplify the effects of drugs targeting the GLXR in speciﬁc
bacteria, although BSO itself has been shown to be only weakly
effective against some strains of E. coli (Romero & Canada, 1991).
Thioredoxin, on the other hand, senses the NADPH pool directly.
Synthetic inhibition of thioredoxin and NADPH production might
also be possible, since mutations in glucose-6-phosphate dehydro-
genase, i.e. favism, are tolerated in the absence of ROS stress
(Scriver, 2001). Thus, toxic side effects might be minimized for the
host organism via direct inhibition of both thioredoxin and glucose-
6-phosphate dehydrogenase should that route be taken.
GLXR and thioredoxin are nonspeciﬁcally inhibited by cisplatin
(Arne ´r et al., 2001) and cadmium (Chrestensen et al., 2000).
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Figure 5
Surface renderings of the Br. melitensis (a), Ba. henselae (b), E. coli (c) and human (d) GLXR domains. The conserved disulﬁde active site is shown in yellow and the HSL
loop regions are shown in cyan, magenta, green and gold as in Fig. 4. The V-shaped pocket amenable to drug design in the bacterial GLXRs is indicated by the red chevron.
The protein poses are rotated 90  relative to Fig. 4(g).Additionally, glutathione analogs are also potent but nonsequence-
speciﬁc inhibitors of GLXR (Ho ¨o ¨g et al., 1982). Because these
compounds are just as likely to disrupt host GLXRs as bacterial
enzymes, they are not viable as drug candidates. Thus, the real
challenge in ﬁnding dithiol active-site inhibitors lies in identifying
compounds that disrupt or covalently react with the dithiol center but
only after interrogating species-speciﬁc features. The relatively close
proximity of the HSL region (Fig. 4g, trapezoid) to the conserved
active site affords a promising option. Surface renderings of the
proteins support this assertion and highlight a V-shaped indentation
bordered on one side by the conserved dithiol and on the other by the
HSL (Figs. 5a,5 b and 5c). This groove is much smaller within the
surface of the human GLXR (Fig. 5d). Thus, it may be possible to
rationally engineer bidentate drugs that anchor themselves into the
region via the HSL by one epitope while attacking the adjacent
dithiol with their other halves. In the case of GLXR, such drugs
would be particularly useful if combined with the aforementioned
BSO compound for perturbing the basal GSH and/or NADPH levels
to enhance ROS-mediated cell death.
The authors wish to thank the whole SSGCID team. This research
was funded under Federal Contract No. HHSN272200700057C from
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services.
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